tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Latest News

Plandai Biotechnology, Inc. Announces Completion of $13 Million Production Facility

Plandai Biotechnology, Inc. Announces Completion of $13 Million Production Facility

LOGAN, UT – December 22, 2014 – Plandaí Biotechnology, Inc. (OTCQB: PLPL) (“Plandaí” or “the Company”), a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced completion of the Company’s production facility in South Africa. Further, the Company announced that samples from the first batch of Phytofare® Catechin Complex, which is derived from green tea, are being delivered to testing facilities for final profiling which will take place once vendors return from holiday. Additionally, samples are being sent to North West University to complete their clinical trials and to potential customers for evaluation. Over the coming days the factory will increase its manufacturing production with the expectation that the Company will then be ready to accept and fill customer orders.

Since beginning the Senteeko project in 2012, Plandaí has expended over $4.5 million in rehabilitating the tea estate and another $8.5 million in building the production facility, for a total investment of over $13 million.

Roger Duffield, Chief Executive Officer at Plandaí Biotechnology, commented, “Bringing a factory of this nature online has been a monumental task. We’re proud that we’ve been able to build the factory onsite at the Senteeko plantation and that the clinical data has thus far supported our position that we can produce highly bioavailable, all-natural nutraceuticals.”

The Senteeko factory encompasses approximately 75,000 sq. ft., is fully automated, and includes management offices and research facilities. At full capacity, the facility can process twenty tons of live plant material every day, averaging approximately eight tons of finished Phytofare® Catechin extract every month during the 8-month tea growing cycle.

Mr. Duffield added, “We currently have enough green tea ready for harvest to allow us to produce about six tons of Phytofare® per month based on estimated yields. We plan on bringing an additional 400 acres online this summer so that production can increase to full capacity. We will stockpile surplus Phytofare® for the dry season so that customer supply is not interrupted. During the summer period, when the tea is dormant, the factory has the ability to process lemons to produce Phytofare® Limonoid Glycoside extract with an estimated capacity of 15 tons per season.”

Mr. Duffield concluded, “Commissioning the Senteeko factory has been a huge milestone for Plandaí. I personally could not be more proud of the Plandaí team and appreciative for the dedication, faith and sacrifices of so many people that helped realize the Plandaí vision.”

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing raw materials on its farms in South Africa, to producing its proprietary Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC’s website located at http://www.sec.gov.
Contact:

Andrew Beyer
Phone: 888-627-6902
Email: investor@Plandaíbiotech.com

0
ContactUs.com